Hemab Therapeutics Holdings

COAG · NASDAQ

$34.17+$2.08 (+6.48%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $32.09

COAG analyst rating

BuyConsensus of 7 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy7
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $62.42 (+82.7% upside)

Low: $58.58
Now: $34.17
High: $68.25

Upgrades and downgrades

The latest rating actions, newest first

COAG analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
JP Morgan	Oct 15, 2026	Initiates	Overweight	$70.00	50%
Rodman & Renshaw	Oct 12, 2026	Initiates	Buy	$56.00	40%
Wedbush	Aug 12, 2026	Maintains	Outperform	$55.00 → $64.00	46%
HC Wainwright & Co.	Aug 11, 2026	Maintains	Buy	$52.00 → $60.00	27%
Jefferies	Jul 13, 2026	Maintains	Buy	$39.00 → $47.00	29%
Wedbush	Jul 13, 2026	Maintains	Outperform	$42.00 → $55.00	46%
HC Wainwright & Co.	Jul 13, 2026	Maintains	Buy	$40.00 → $52.00	27%
HC Wainwright & Co.	Jun 26, 2026	Maintains	Buy	$40.00	27%
HC Wainwright & Co.	Jun 17, 2026	Initiates	Buy	$40.00	27%
Wedbush	May 26, 2026	Initiates	Outperform	$42.00	46%

The case for and against

Updated Oct 18, 2026

Bull case

Hemab Therapeutics Hldgs is attractive because its pipeline shows multiple differentiated shots on goal, led by sutacimig in Glanzmann thrombasthenia and Factor VII deficiency, plus HMB-002 and HMB-003 in under-served bleeding disorders. The company’s 2Q26 total operating expenses of $26.1M and EPS of ($0.80) reflect active development rather than weak demand, while $457.5M in cash and equivalents suggests runway into 2030. Fundamentally, the outlook is supported by encouraging proof-of-mechanism and early efficacy signals, including FDA endorsement for sutacimig Phase 3 advancement, which improves the odds of future value creation across the platform.

Bear case

Hemab Therapeutics Hldgs is a clinically early, unprofitable biotech whose value depends heavily on unproven assets, with sutacimig and HMB-002 carrying only partial probability-adjusted success assumptions across GT, FVII deficiency, and VWD. The valuation framework itself signals fragility, using a 12% discount rate, a -25% terminal value, and a need for about $150M in additional capital through 2040, while still assuming runway only into 2030. The biggest fundamental downside is that poorer-than-expected clinical data, FDA non-approval, safety or efficacy issues, and intensifying competition could quickly impair both commercialization prospects and financing flexibility.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.